Revelation Biosciences (REVB) Stock Analysis

What Revelation Biosciences does

Revelation Biosciences, Inc. is a biopharmaceutical firm currently in its clinical development phase, dedicated to the advancement and commercialization of treatments and diagnostic tools targeting the immune system. The company's therapeutic pipeline includes promising candidates such as GEM-AKI, which is being developed as a potential therapy for both the prevention and management of acute kidney injury, and GEM-CKD, intended for the prevention and treatment of chronic kidney disease. Established in 2019, this San Diego, California-based enterprise was formerly known as Petra Acquisition, Inc., before officially adopting the name Revelation Biosciences, Inc. in January 2022.

Key metrics

ETFs linked to REVB

Broad-market and Healthcare sector ETFs an investor holding Revelation Biosciences is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how REVB fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Revelation Biosciences?

Revelation Biosciences trades under the ticker REVB on NASDAQ.

Which exchange is REVB listed on?

REVB is listed on NASDAQ.

What sector does Revelation Biosciences operate in?

Revelation Biosciences is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze REVB in a portfolio?

PortView shows REVB's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.